These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 39130906)

  • 1. Combined Pimavanserin and Maintenance Electroconvulsive Therapy: A Novel Approach to Parkinson's Disease Psychosis.
    Imlay RK; Alsayed M; Starcher M; Tager A; Griffith J
    Cureus; 2024 Jul; 16(7):e64316. PubMed ID: 39130906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice.
    Dashtipour K; Gupta F; Hauser RA; Karunapuzha CA; Morgan JC
    Parkinsons Dis; 2021; 2021():2603641. PubMed ID: 33489083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
    Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
    Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis.
    Isaacson SH; Pahwa R; Pagan F; Abler V; Truong D
    Clin Park Relat Disord; 2024; 10():100256. PubMed ID: 38770047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychosis in Parkinson's Disease: Looking Beyond Dopaminergic Treatments.
    Rojas M; Chávez-Castillo M; Duran P; Ortega Á; Bautista-Sandoval MJ; Salazar J; Riaño-Garzón M; Chacín M; Medina-Ortiz O; Palmar J; Cudris-Torres L; Bermúdez V
    Curr Pharm Des; 2022; 28(33):2725-2741. PubMed ID: 36321314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pimavanserin in the Treatment of Parkinson's Disease Psychosis: Meta-analysis and Meta-regression of Randomized Clinical Trials.
    Mansuri Z; Reddy A; Vadukapuram R; Trivedi C; Amara A
    Innov Clin Neurosci; 2022; 19(1-3):46-51. PubMed ID: 35382074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the treatment of Parkinson's disease psychosis: role of pimavanserin.
    Combs BL; Cox AG
    Neuropsychiatr Dis Treat; 2017; 13():737-744. PubMed ID: 28331324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
    Kianirad Y; Simuni T
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin.
    Lyons KE; Pahwa R; Hermanowicz N; Davis T; Pagan F; Isaacson S
    Expert Rev Clin Pharmacol; 2019 Jul; 12(7):681-691. PubMed ID: 31159608
    [No Abstract]   [Full Text] [Related]  

  • 10. Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis.
    Tampi RR; Tampi DJ; Young JJ; Balachandran S; Hoq RA; Manikkara G
    World J Psychiatry; 2019 Jun; 9(3):47-54. PubMed ID: 31211112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.
    Hacksell U; Burstein ES; McFarland K; Mills RG; Williams H
    Neurochem Res; 2014 Oct; 39(10):2008-17. PubMed ID: 24682754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychosis in Parkinson's Disease: Current Treatment Options and Impact on Patients and Caregivers.
    Segal GS; Xie SJ; Paracha SU; Grossberg GT
    J Geriatr Psychiatry Neurol; 2021 Jul; 34(4):274-279. PubMed ID: 34219522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy.
    Usui C; Hatta K; Doi N; Kubo S; Kamigaichi R; Nakanishi A; Nakamura H; Hattori N; Arai H
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1704-8. PubMed ID: 21605615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's Disease Psychosis and the Marketing of Pimavanserin.
    Daeschler D; Fugh-Berman A
    Int J Soc Determinants Health Health Serv; 2024 Jul; 54(3):272-284. PubMed ID: 38592164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions.
    Isaacson SH; Citrome L
    Expert Opin Drug Saf; 2022 Jul; 21(7):873-879. PubMed ID: 35466847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson's Disease Psychosis: Systematic Review and Network Meta-Analysis.
    Yunusa I; Rashid N; Seyedin R; Paratane D; Rajagopalan K
    J Geriatr Psychiatry Neurol; 2023 Sep; 36(5):417-432. PubMed ID: 36720473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease.
    Hermanowicz S; Hermanowicz N
    Expert Rev Neurother; 2016 Jun; 16(6):625-33. PubMed ID: 26908168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Chendo I; Ferreira JJ
    Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden.
    Fredericks D; Norton JC; Atchison C; Schoenhaus R; Pill MW
    Am J Manag Care; 2017 Apr; 23(5 Suppl):S83-S92. PubMed ID: 28715903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening, Diagnosis, and Management of Parkinson's Disease Psychosis: Recommendations From an Expert Panel.
    Pahwa R; Isaacson SH; Small GW; Torres-Yaghi Y; Pagan F; Sabbagh M
    Neurol Ther; 2022 Dec; 11(4):1571-1582. PubMed ID: 35906500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.